Peptide Suppliers AI Visibility Ranking Trends - November 2026
Tracking how AI platforms recommend peptide suppliers ai visibility ranking trends. Updated monthly since April 2026.

On this page
Answer capsule
The November 2026 Peptide Suppliers benchmark compares 7 companies across 453 AI answers that met its inclusion rules. Phoenix Pharmaceuticals leads with 117 recommendations (25.83% of answers). At least one tracked company was recommended in 222 answers; some answers recommended several companies.
The rankings distinguish being mentioned from receiving an affirmative recommendation, then examine placement and the wording used about each company. This edition establishes a baseline; earlier editions measured on a different basis are not used to claim a performance trend. These results describe the answers reviewed, not product quality or customer satisfaction. Differences between monthly samples limit comparisons and do not establish why a result changed.
For the strategic interpretation of this benchmark, read CiteWorks Studio's analysis of How AI Search Is Recommending Peptide Suppliers
Industry leaderboard
Questions This Section Answers
- How do Peptide Suppliers rank by recorded AI recommendations in November 2026?
Rank | Company | Recommendations | Recommendation rate | Mention rate | Top 3 rate | #1 rate | Net sentiment |
|---|---|---|---|---|---|---|---|
1 | Phoenix Pharmaceuticals | 117 | 25.83% | 39.29% | 20.75% | 12.80% | 0.75 |
2 | Biotech Peptides | 91 | 20.09% | 31.35% | 15.45% | 6.18% | 0.67 |
3 | Core Peptides | 72 | 15.89% | 33.55% | 13.02% | 3.75% | 0.49 |
4 | AminoVault | 27 | 5.96% | 7.28% | 3.75% | 1.10% | 0.82 |
5 | Peptides Source | 4 | 0.88% | 2.21% | 0.66% | 0.22% | 0.40 |
6 | Blue Sky Peptide | 3 | 0.66% | 7.95% | 0.66% | 0.00% | -0.08 |
7 | Peptide Tech | 0 | 0.00% | 1.55% | 0.00% | 0.00% | 0.00 |
The leaderboard orders companies by how many recorded answers included an affirmative recommendation. That count is a measure of endorsement frequency in the reviewed answers, not of sales, market share or product quality. A company can appear often yet be recommended rarely, so mention counts and recommendation counts answer different questions.
Ties would require equal recommendation counts; the printed order should be read as recorded, not as a margin of superiority. Placement figures are nested inside recommendations rather than added to them, and framing describes wording rather than customer sentiment.
Key findings
Tracked-company answer coverage
Questions This Section Answers
- How often did the November 2026 Peptide Suppliers answer sample recommend any tracked company?
Answer-level result | Qualified answers | Share of qualified answers |
|---|---|---|
At least one tracked company mentioned | 414 | 91.39% |
At least one tracked company recommended | 222 | 49.01% |
No tracked company recommended | 231 | 50.99% |
Multiple tracked companies recommended | 78 | 17.22% |
222 distinct answers recommended at least one tracked company. Counting each company recommendation separately gives 314, because an answer can recommend several companies. Answers with no tracked recommendation may still have recommended companies outside this comparison.
Most qualified answers named at least one tracked company, but only about half carried an affirmative recommendation for one. That gap is the central coverage distinction: appearing in an answer is not the same as being endorsed in it. Answers without a tracked recommendation may still have named companies outside this comparison.
Because one answer can recommend several companies, company-level totals exceed the number of distinct answers with any recommendation. Overlap is therefore expected, and it should not be read as overall market dominance.
Reach and affirmative recommendation
Phoenix Pharmaceuticals ranks 1 by recommendation count. Mentions: 178 (39.29%); recommendations: 117 (25.83%). Top 3 placements: 94 (20.75%); first-place placements: 58 (12.80%).
Wording about the company: 133 positive, 45 neutral, 0 negative mentions. The proportion of mentions that also included a recommendation was 65.7%. The net framing score was 0.75 (defined in Methodology).
61 mentions had no recorded recommendation. Of recorded recommendations, 80.34% were Top 3 and 49.57% were first-place.
Phoenix Pharmaceuticals leads on recommendation count, and its mentions frequently also carried an endorsement. Still, a substantial share of its appearances recorded no recommendation, so reach and endorsement should be read as separate measures rather than one implying the other.
Placement figures are subsets of its recommendations, not additional wins. The recorded wording was largely positive with no negative mentions, but framing describes how the company was described in these answers, not why recommendations occurred.
Recommendation order and placement
Company | Mentions | Recommendation-to-mention ratio | Top 3 / #1 counts | Positive / neutral / negative mentions |
|---|---|---|---|---|
Phoenix Pharmaceuticals | 178 | 65.7% | 94 / 58 | 133 / 45 / 0 |
Biotech Peptides | 142 | 64.1% | 70 / 28 | 95 / 47 / 0 |
Core Peptides | 152 | 47.4% | 59 / 17 | 79 / 69 / 4 |
AminoVault | 33 | 81.8% | 17 / 5 | 27 / 6 / 0 |
Peptides Source | 10 | 40.0% | 3 / 1 | 4 / 6 / 0 |
Blue Sky Peptide | 36 | 8.3% | 3 / 0 | 6 / 21 / 9 |
Peptide Tech | 7 | 0.0% | 0 / 0 | 0 / 7 / 0 |
Placement describes where a recommended company sat within an answer's ordering. Top 3 and first-place counts are contained within recommendations, so they should not be summed with recommendation totals or treated as separate victories. A high first-place share means a large portion of that company's recorded recommendations appeared at the top of the answer.
The recommendation-to-mention ratio compares two recorded counts. It reflects answer wording, not customer conversion, and a strong ratio on a small base warrants caution.
Classified framing in context
Company | Positive | Neutral | Negative |
|---|---|---|---|
Phoenix Pharmaceuticals | 133 | 45 | 0 |
Biotech Peptides | 95 | 47 | 0 |
Core Peptides | 79 | 69 | 4 |
AminoVault | 27 | 6 | 0 |
Peptides Source | 4 | 6 | 0 |
Blue Sky Peptide | 6 | 21 | 9 |
Peptide Tech | 0 | 7 | 0 |
Framing classifies the wording used about each company in the selected answers: positive, neutral or negative. It is not a reputation score, customer sentiment measure or judgment of company quality. Neutral wording is common and does not indicate disapproval.
Differences in framing across companies describe how these answers phrased their references. They do not establish why some appearances carried recommendations and others did not, and they should not be read as evidence of source influence.
Company results in detail
Phoenix Pharmaceuticals
Questions This Section Answers
- What do the November 2026 AI answer results show about Phoenix Pharmaceuticals mentions, recommendations and placement?
Phoenix Pharmaceuticals ranks 1 by recommendation count. Mentions: 178 (39.29%); recommendations: 117 (25.83%). Top 3 placements: 94 (20.75%); first-place placements: 58 (12.80%).
Wording about the company: 133 positive, 45 neutral, 0 negative mentions. The proportion of mentions that also included a recommendation was 65.7%. The net framing score was 0.75 (defined in Methodology).
61 mentions had no recorded recommendation. Of recorded recommendations, 80.34% were Top 3 and 49.57% were first-place.
This edition establishes a broader research baseline. Earlier editions used a narrower set of questions, so their figures are not treated as a performance trend.
Phoenix Pharmaceuticals leads this edition on recommendation count, with mentions appearing in a large share of qualified answers. Most of its recorded recommendations also placed it in the Top 3, and roughly half of those reached first place, indicating strong positioning within answers where it was endorsed.
Its wording was predominantly positive with no negative mentions, and most appearances also carried a recommendation. The remaining appearances recorded no endorsement, so reach exceeded affirmative recommendation.
Biotech Peptides
Questions This Section Answers
- What do the November 2026 AI answer results show about Biotech Peptides mentions, recommendations and placement?
Biotech Peptides ranks 2 by recommendation count. Mentions: 142 (31.35%); recommendations: 91 (20.09%). Top 3 placements: 70 (15.45%); first-place placements: 28 (6.18%).
Wording about the company: 95 positive, 47 neutral, 0 negative mentions. The proportion of mentions that also included a recommendation was 64.1%. The net framing score was 0.67 (defined in Methodology).
51 mentions had no recorded recommendation. Of recorded recommendations, 76.92% were Top 3 and 30.77% were first-place.
This edition establishes a broader research baseline. Earlier editions used a narrower set of questions, so their figures are not treated as a performance trend.
Biotech Peptides ranks second on recommendation count, with a mention presence somewhat below the leader's. Its recommendations were frequently placed in the Top 3, though first-place placements were a smaller portion of its endorsements, suggesting it was often endorsed without occupying the top position.
Wording was positive or neutral with no negative mentions, and most appearances included a recommendation. The gap between mentions and recommendations is a recorded count difference, not evidence about why some answers omitted an endorsement.
Core Peptides
Questions This Section Answers
- What do the November 2026 AI answer results show about Core Peptides mentions, recommendations and placement?
Core Peptides ranks 3 by recommendation count. Mentions: 152 (33.55%); recommendations: 72 (15.89%). Top 3 placements: 59 (13.02%); first-place placements: 17 (3.75%).
Wording about the company: 79 positive, 69 neutral, 4 negative mentions. The proportion of mentions that also included a recommendation was 47.4%. The net framing score was 0.49 (defined in Methodology).
80 mentions had no recorded recommendation. Of recorded recommendations, 81.94% were Top 3 and 23.61% were first-place.
This edition establishes a broader research baseline. Earlier editions used a narrower set of questions, so their figures are not treated as a performance trend.
Core Peptides recorded more mentions than Biotech Peptides but fewer recommendations, so its recommendation-to-mention ratio was noticeably lower. Its placements were mostly within the Top 3, with first-place results a smaller subset. This profile shows how a strong mention presence need not translate into a comparable endorsement count.
Its wording was largely positive or neutral, with a small number of negative mentions recorded. Framing describes the selected answers only and does not explain the recommendation pattern.
AminoVault
Questions This Section Answers
- What do the November 2026 AI answer results show about AminoVault mentions, recommendations and placement?
AminoVault ranks 4 by recommendation count. Mentions: 33 (7.28%); recommendations: 27 (5.96%). Top 3 placements: 17 (3.75%); first-place placements: 5 (1.10%).
Wording about the company: 27 positive, 6 neutral, 0 negative mentions. The proportion of mentions that also included a recommendation was 81.8%. The net framing score was 0.82 (defined in Methodology).
6 mentions had no recorded recommendation. Of recorded recommendations, 62.96% were Top 3 and 18.52% were first-place.
This edition establishes a broader research baseline. Earlier editions used a narrower set of questions, so their figures are not treated as a performance trend.
AminoVault appears in far fewer answers than the three leaders, but a high proportion of its mentions also carried a recommendation. That ratio rests on a comparatively small base, so it should be read as a description of these answers rather than a stable characteristic.
Its placements were mostly within the Top 3, with first-place results a smaller subset. Wording was positive or neutral with no negative mentions recorded.
Peptides Source
Questions This Section Answers
- What do the November 2026 AI answer results show about Peptides Source mentions, recommendations and placement?
Peptides Source ranks 5 by recommendation count. Mentions: 10 (2.21%); recommendations: 4 (0.88%). Top 3 placements: 3 (0.66%); first-place placements: 1 (0.22%).
Wording about the company: 4 positive, 6 neutral, 0 negative mentions. The proportion of mentions that also included a recommendation was 40.0%. The net framing score was 0.40 (defined in Methodology).
6 mentions had no recorded recommendation. Of recorded recommendations, 75.00% were Top 3 and 25.00% were first-place.
This edition establishes a broader research baseline. Earlier editions used a narrower set of questions, so their figures are not treated as a performance trend.
Peptides Source recorded a small number of mentions and fewer recommendations, so its profile rests on a limited base. Its recommendation-to-mention ratio was moderate, and its placements were few, mostly within the Top 3 with a single first-place result.
Wording was split between positive and neutral with no negative mentions. With so few appearances, the ratios and placement shares should be treated as descriptive of this answer set rather than as stable measures.
Blue Sky Peptide
Questions This Section Answers
- What do the November 2026 AI answer results show about Blue Sky Peptide mentions, recommendations and placement?
Blue Sky Peptide ranks 6 by recommendation count. Mentions: 36 (7.95%); recommendations: 3 (0.66%). Top 3 placements: 3 (0.66%); first-place placements: 0 (0.00%).
Wording about the company: 6 positive, 21 neutral, 9 negative mentions. The proportion of mentions that also included a recommendation was 8.3%. The net framing score was -0.08 (defined in Methodology).
33 mentions had no recorded recommendation. Of recorded recommendations, 100.00% were Top 3 and 0.00% were first-place.
This edition establishes a broader research baseline. Earlier editions used a narrower set of questions, so their figures are not treated as a performance trend.
Blue Sky Peptide was mentioned more often than several lower-ranked companies but recorded very few recommendations, giving it a low recommendation-to-mention ratio. Its few placements were all within the Top 3, with no first-place results.
Its wording included the most negative mentions among tracked companies alongside many neutral ones, producing a slightly negative net framing score. Framing describes these answers, not customer sentiment or company quality.
Peptide Tech
Questions This Section Answers
- What do the November 2026 AI answer results show about Peptide Tech mentions, recommendations and placement?
Peptide Tech ranks 7 by recommendation count. Mentions: 7 (1.55%); recommendations: 0 (0.00%). Top 3 placements: 0 (0.00%); first-place placements: 0 (0.00%).
Wording about the company: 0 positive, 7 neutral, 0 negative mentions. The proportion of mentions that also included a recommendation was 0.0%. The net framing score was 0.00 (defined in Methodology).
7 mentions had no recorded recommendation. Of recorded recommendations, Unavailable were Top 3 and Unavailable were first-place.
This edition establishes a broader research baseline. Earlier editions used a narrower set of questions, so their figures are not treated as a performance trend.
Peptide Tech recorded a small number of mentions and no recommendations in this edition. Its placement counts are therefore zero, and ratios requiring a nonzero recommendation base are undefined rather than missing observations.
All of its recorded wording was neutral, with no positive or negative mentions. This is a measured zero in the selected answers, not evidence about the company beyond them.
Earlier ranking snapshot context
Questions This Section Answers
- How do the available Peptide Suppliers snapshots from July 2026 to November 2026 differ in recommendation coverage and measurement scope?
Company | Nov 2026 |
|---|---|
Phoenix Pharmaceuticals | 117 / 453 (25.83%) |
Biotech Peptides | 91 / 453 (20.09%) |
Core Peptides | 72 / 453 (15.89%) |
AminoVault | 27 / 453 (5.96%) |
Peptides Source | 4 / 453 (0.88%) |
Blue Sky Peptide | 3 / 453 (0.66%) |
Peptide Tech | 0 / 453 (0.00%) |
Company | Nov 2026 rank |
|---|---|
Phoenix Pharmaceuticals | 1 |
Biotech Peptides | 2 |
Core Peptides | 3 |
AminoVault | 4 |
Peptides Source | 5 |
Blue Sky Peptide | 6 |
Peptide Tech | 7 |
Only months with verified results are shown. Monthly sample coverage is listed in Methodology.
The November snapshot is a single selected sample of AI answers, and the printed counts and rates should be read together rather than in isolation. Earlier editions used a narrower question set, so their figures are not treated as a performance trend and do not establish rank stability.
Monthly samples are separate, and smaller answer totals in other periods would not by themselves explain any difference in a company's counts or rates.
AI recommendation trend
Observed recommendation rate (%), Nov 2026
- Phoenix Pharmaceuticalsno changeNov 202625.8%
- Biotech Peptidesno changeNov 202620.1%
- Core Peptidesno changeNov 202615.9%
- AminoVaultno changeNov 20266.0%
- Peptides Sourceno changeNov 20260.9%
- Blue Sky Peptideno changeNov 20260.7%
- Peptide Techno changeNov 20260.0%
What the November Rankings Show
These rankings answer several distinct questions. Reach asks how often a company appeared in the reviewed answers. Recommendation asks how often an appearance carried an affirmative endorsement. Placement asks where an endorsed company sat within the answer's ordering, and framing asks how the wording characterized it. Each measure can diverge from the others.
A company may be mentioned widely yet endorsed rarely, or endorsed often on a small base. Placement figures are nested within recommendations, so they refine rather than add to the endorsement count. Framing describes wording, not customer sentiment, and none of these measures establishes why an answer recommended a company or what its products are like.
The results describe the AI answers reviewed, not independently verified facts about the companies. They are a research baseline for this edition, not a commercial assessment.
Methodology
Questions This Section Answers
- How were the November 2026 Peptide Suppliers AI visibility measures counted, and what do they not establish?
Question-category coverage: 9 of 11 planned question categories contributed usable observations; 2 contributed none. This describes question-category coverage, not demonstrated platform outages. Findings apply to the available answer set. Mentions require the company to be identified in the answer; incidental uses of its name as an ordinary word are not counted. Mentions require the company to be identified in the answer; incidental uses of its name as an ordinary word are not counted.
The month in the title is the reporting period. The exact dates when the original AI answers were collected have not been verified.
Each company is counted at most once in each answer that meets the benchmark rules. A recommendation requires both an affirmative endorsement and positive wording. Mention, recommendation, Top 3 and first-place rates use the full benchmark answer total. Top 3 and first-place results are included within recommendations, not added to them.
The recommendation-to-mention ratio divides recommendations by mentions. It describes AI answer wording, not customer conversion. Net framing is positive minus negative mentions, divided by all mentions, on a scale from -1 to +1. It does not measure customer satisfaction or company quality.
Market: US; 7 tracked companies. AI services represented: ChatGPT, Copilot, Gemini, Google AI Mode, Google AI Overviews, Perplexity.
Research screening totals (answer observations can include repeated questions):
Screening measure | Count |
|---|---|
Answers eligible for the limited email report | 317 |
Answers marked relevant during screening | 453 |
Answers marked reserved (screening label) | 136 |
Answers marked irrelevant during screening | 101 |
Captured answer observations | 554 |
Distinct questions | 359 |
Answer observations marked as mentioning a brand | 505 |
Email eligibility and reservation labels do not limit this article: all relevant captured answers are included in its rate denominator.
One answer can mention or recommend several companies. Adding company totals would therefore count some answers more than once. The results describe the AI answers reviewed, not independently verified facts about the companies or their products.
Monthly sample coverage:
Reporting month | Answers included | AI services covered | Services |
|---|---|---|---|
Nov 2026 | 453 | 6 | ChatGPT, Copilot, Gemini, Google AI Mode, Google AI Overviews, Perplexity |
Earlier editions (July 2026, August 2026, September 2026 and October 2026) used a narrower set of questions. This edition includes all captured answers screened as relevant and establishes a broader baseline. Earlier figures remain in the archive; they are not used to claim a change in performance.
Future editions using the same screening scope can be compared against this baseline.
These findings apply to the available answer set. Mentions require the company to be identified in the answer, and each company is counted at most once per answer. A recommendation requires both an affirmative endorsement and positive wording. Mention, recommendation, Top 3 and first-place rates use the full benchmark answer total, and placement results are included within recommendations rather than added to them.
The recommendation-to-mention ratio describes answer wording, not customer conversion. Net framing is positive minus negative mentions divided by all mentions, and it does not measure customer satisfaction or company quality. One answer can mention or recommend several companies, so company totals overlap and should not be summed. The reporting month is the period label; exact collection dates were not verified, and question-category coverage was partial. Earlier editions used a narrower question set and are not used to claim performance change.
Archived editions
Browse earlier published research snapshots for this article. The latest edition remains at the current URL.
Keep reading
Related posts
Industry Reports
Peptide API Manufacturing AI Visibility Ranking Trends - November 2026
Read this blog on LLM Authority Index.
ReadIndustry Reports
Criminal Defense Lawyers AI Visibility Ranking Trends - November 2026
Read this blog on LLM Authority Index.
ReadIndustry Reports
Credit Cards for Building Credit AI Visibility Ranking Trends - November 2026
Read this blog on LLM Authority Index.
Read